Noticias y Actividades de Norgine

Norgine tiene presencia directa en 3 países.

Norgine posee 3 subsidiarias incluyendo Norgine France, Norgine UK y Norgine Ventures.

Ellos se encuentran en:

• Farmacia75%
• Fondo25%

Ver el organigrama con sus 30 ejecutivos principales

Biografías más buscadas en Norgine

• Janneke Van Der Kamp, Chief Executive Officer
• Peter Stein, Executive Chairman of the Board
• Saulo Martiniano, Chief Operating Officer

Recientes movimientos de ejecutivos en Norgine

• Janneke Van Der Kamp se incorporará a la empresa como Chief Executive Officer el 1 de ene.. de 2025  (noticia publicada el 4 de octubre de 2024).
• Christopher Bath, Chief Executive Officer, ha dejado la empresa  (noticia publicada el 4 de octubre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Norgine.

Norgine tiene 1.824 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Roche (Suiza).

Popular M&A news in Farmacia

• Cyclo Therapeutics ha Rafael Holdings adquirido (publicado el 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado el 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Seth Harrison - Chairman and Director en Braeburn Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Norgine

• X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. - Norgine
• Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - Norgine
• X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand - Norgine
• Norgine Announces Appointment of New CEO Janneke van der Kamp - Norgine
• Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - Norgine
• Norgine receives positive CHMP opinion recommending approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the treatment of malignant hyperthermia - Norgine
• Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - Norgine
• Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
• European study highlights need to improve the quality of conversations about induction of labour (IoL) in  clinical settings
• Norgine Announces Closing of Investment from Goldman Sachs Asset Management
• View more press releases Close

Redes sociales sobre Norgine

• Norgine en Wikipedia, Google News y Yahoo Finance
• Norgine en LinkedIn, Twitter y YouTube